drugset / Trial / NCT05645887

Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.

NCT05645887

Phase 2 Withdrawn Albimmune SL
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this phase 2, multicenter, randomized, controlled study is to evaluate the effect of albumin treatment on B cell and other immune cell gene exptression in adults with septic shock.

Timeline

Start
2024-02
Primary completion
2024-05-23
Completion
2024-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 20 % Intravenous
Subject Albumin Protein / enzyme biologic 300 ml Intravenous
Subject Albumin Protein / enzyme biologic 60 g Intravenous